Chen, Chih-Wei http://orcid.org/0000-0002-1401-4820
Su, Chi
Huang, Chang-Yu http://orcid.org/0000-0001-7430-2085
Huang, Xuan-Rong
Cuili, Xiaojing http://orcid.org/0000-0002-3819-2509
Chao, Tung http://orcid.org/0000-0003-3641-4996
Fan, Chun-Hsiang
Ting, Cheng-Wei
Tsai, Yi-Wei
Yang, Kai-Chien
Yeh, Ti-Yen
Hsieh, Sung-Tsang http://orcid.org/0000-0002-3188-8482
Chen, Yi-Ju http://orcid.org/0000-0002-7203-9188
Feng, Yuxi
Hunter, Tony http://orcid.org/0000-0002-7691-6993
Chang, Zee-Fen http://orcid.org/0000-0003-3011-284X
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (NSCT 111-2326-B-002-022, NSCT 111-2634-F-002-017, NSCT 111-2320-B-002-088)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA242443)
Article History
Received: 11 July 2023
Accepted: 23 February 2024
First Online: 13 March 2024
Competing interests
: T.H. holds a patent describing the generation and use of phosphohistidine-specific monoclonal antibodies. The remaining authors declare no competing interests.